Heres what the likely new FDA director has in mind for the

first_imgThe U.S. Food and Drug Administration/FLICKR Here’s what the likely new FDA director has in mind for the nation’s medicine cabinet Other potential reforms include the possible quick adoption of new devices that could be used to  improve the kind of medtech Apple, Verily and others have been working on.Gottlieb has also backed the publication of the FDA’s complete response letters, detailing the reasons why the agency rejects a drug. Over the years regulators have routinely complained that many companies have been less than honest in recounting the FDA’s position on a drug. The FDA is currently restricted by law in its public discussion about a new drug approval.The move could also spell relief for Amicus Therapeutics and CEO John Crowley, who personally lobbied the president on the FDA’s decision to delay any final decision on their drug for Fabry disease so they could see the results of a safety study in 2019. By John Carroll, Endpoints NewsMar. 10, 2017 , 2:45 PM Click to view the privacy policy. Required fields are indicated by an asterisk (*) Sign up for our daily newsletter Get more great content like this delivered right to you! Country Email Country * Afghanistan Aland Islands Albania Algeria Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia, Plurinational State of Bonaire, Sint Eustatius and Saba Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Congo, the Democratic Republic of the Cook Islands Costa Rica Cote d’Ivoire Croatia Cuba Curaçao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands (Malvinas) Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Holy See (Vatican City State) Honduras Hungary Iceland India Indonesia Iran, Islamic Republic of Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Korea, Democratic People’s Republic of Korea, Republic of Kuwait Kyrgyzstan Lao People’s Democratic Republic Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, the former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Martinique Mauritania Mauritius Mayotte Mexico Moldova, Republic of Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Norway Oman Pakistan Palestine Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Qatar Reunion Romania Russian Federation Rwanda Saint Barthélemy Saint Helena, Ascension and Tristan da Cunha Saint Kitts and Nevis Saint Lucia Saint Martin (French part) Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Sint Maarten (Dutch part) Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and the South Sandwich Islands South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Tanzania, United Republic of Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States Uruguay Uzbekistan Vanuatu Venezuela, Bolivarian Republic of Vietnam Virgin Islands, British Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe Left out in the move: Jim O’Neill. The close associate of Peter Thiel, O’Neill famously suggested that drugs should be approved based on safety alone, letting consumers sort out what works. That left many fearing that Trump intended to toss out the regulatory framework for new drug approvals, raising fears that his idea of competition would allow de facto placebos to compete for market share.Trump has repeatedly criticized biopharma for outrageously high drug prices, vowing to simplify the drug development process as he also sought to dramatically lower the price of drugs.Reprinted from Endpoints News. Copyright 2017. Endpoints News reports and analyzes the top global biotech and pharmaceutical R&D news of the day. Sign up for its free reports at Originally published by Endpoints NewsCiting sources, Reuters reported Friday afternoon that President Trump is close to naming Scott Gottlieb as the next FDA commissioner. The news could come any moment, according to the wire service, resolving an issue that has huge implications for biopharma.If the story holds up, Gottlieb’s nomination would be widely applauded by the biopharma industry, which would likely see the move as a commitment for continued reform without the kind of wholesale deregulation that would scuttle the agency’s gold standard for drug reviews.As I reported two weeks ago, Gottlieb has mapped out an aggressive reform agenda in anticipation of this appointment.According to his statements as well as comments to people familiar with his thinking on the FDA, Gottlieb intends to shoot for the rapid approval of complex generics, ushering in a wave of less expensive rivals to some of the biggest blockbusters on the market. He’s also likely to spur the FDA to follow the course laid out by agency cancer czar Richard Pazdur in speeding new approvals, possibly setting up a special unit aimed at orphan drugs to hasten OKs with smaller, better designed clinical trials. Read more…last_img

Leave a Reply

Your email address will not be published. Required fields are marked *